It can be explained that the HSA–ICG–PFTBA cannot uniformly distribute throughout the whole body due to the instability of the nanoprobe and immune system clearance because of the absence of cancer cell membrane coating, which was in accordance with the results of the ICG release study (Fig. 2b). The gene discussed is ALB; the disease is cancer.